AQST stock icon

Aquestive Therapeutics
AQST

$2.67
2.56%
 

About: Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Sympazan Oral Film, Suboxone Sublingual Film, Exservan Oral Film, and Zuplenz. The product pipeline includes Libervant Buccal Film, AQST-108, and AQST-305. The majority of its revenue comes from the United States.

Employees: 135

0
Funds holding %
of 6,702 funds
0
Analysts bullish %
of 13 analysts
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

364% more first-time investments, than exits

New positions opened: 51 | Existing positions closed: 11

268% more capital invested

Capital invested by funds: $48.1M [Q4 2023] → $177M (+$129M) [Q1 2024]

115% more call options, than puts

Call options by funds: $4.24M | Put options by funds: $1.97M

70% more funds holding

Funds holding: 57 [Q4 2023] → 97 (+40) [Q1 2024]

64% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 14

10.49% more ownership

Funds ownership: 35.63% [Q4 2023] → 46.12% (+10.49%) [Q1 2024]

0% more funds holding in top 10

Funds holding in top 10: 3 [Q4 2023] → 3 (+0) [Q1 2024]

Research analyst outlook

13 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$7
162%
upside
Avg. target
$8.69
226%
upside
High target
$10
275%
upside

13 analyst ratings

13 positive
100%
neutral
0%
negative
0%
JMP Securities
Jason Butler
237%upside
$9
Market Outperform
Reiterated
26 Jun 2024
HC Wainwright & Co.
Raghuram Selvaraju
237%upside
$9
Buy
Reiterated
5 Jun 2024
Leerink Partners
Roanna Ruiz
200%upside
$8
Outperform
Initiated
10 May 2024
HC Wainwright & Co.
Raghuram Selvaraju
237%upside
$9
Buy
Reiterated
9 May 2024
HC Wainwright & Co.
Raghuram Selvaraju
237%upside
$9
Buy
Reiterated
30 Apr 2024

Financial journalist opinion